Foster and Murray (2026) describe the Laugier-Hunziker pattern: discrete pigmented macules on the oral mucosa and lips, sometimes accompanied by longitudinal nail pigmentation
Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
Glutathione is widely used by dermatologists all over the world during various skin treatments and therapies
For people struggling with obesity or weight-related health risks, GLP-1 medications have emerged as highly effective solutions
Moreover, an abundance of iron and susceptibility to oxidative stress have resulted in the hypothesis that erythrocytes might undergo ferroptosis, an iron-driven ROS-dependent RCD [78]
The Four Stages of Cellulite Stage 0: No dimples when standing or lying down
